- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Biodesix Inc (BDSX)
The Biodesix share price today is 30.600, view NASDAQ BDSX stock exchange data. Track the latest Biodesix share price with real-time updates on BDSX stock performance including market cap, day range, 52-week range and dividend yield. Access BDSX charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
28.000
31.310
52 wk Range
5.260
31.310
Unusual trading volume
1/3
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
28.00031.310
52 wk Range
5.26031.310
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BDSX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
34.000
Upside
+11.11%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
High return over the last year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 34.000
(+11.11% Upside)
Biodesix Inc Earnings Call Summary for Q2/2026
- Biodesix Q2 2026 revenue rose 34% YoY to $26.9M, beating $25.93M estimate; shares fell 5% after-hours despite the beat.
- Diagnostic testing revenue jumped 42% to $25.4M; gross margin reached 82%, up 200 bps YoY, marking fifth consecutive quarter above 80%.
- Net loss narrowed 37% to $7.3M; adjusted EBITDA loss improved 56% to $3.2M as operating expenses rose only 7% versus 34% revenue growth.
- Company maintained FY 2026 guidance of $108M-$114M revenue, implying slower H2 growth of 16%-22% versus strong first-half performance.
- Management expects 80%+ gross margins to continue; plans to add 6-8 sales reps quarterly, reaching ~120 by year-end to drive adoption.
Last Updated: 06-08-2026, 02:42 am
Read Full TranscriptEarnings
Latest Release
05-08-2026
EPS / Forecast
-0.71 / -0.90
Revenue / Forecast
26.9M / 25.96M
Compare BDSX to Peers and Sector
Metrics to compare | BDSX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBDSXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −11.6x | −6.4x | −0.4x | |
PEG Ratio | −0.24 | −0.24 | 0.00 | |
Price/Book | 35.3x | 7.1x | 2.6x | |
Price / LTM Sales | 3.1x | 4.3x | 3.1x | |
Upside (Analyst Target) | 19.3% | 6.3% | 46.0% | |
Fair Value Upside | Unlock | −3.7% | 5.3% | Unlock |
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient’s immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. Further, it operates laboratories. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Biodesix (BDSX) Share Price Today?
The Biodesix share price today is 30.600.
What is the current Biodesix (BDSX) share price and day range?
As of 27-08-2026, the Biodesix share price is 30.600, with a previous close of 30.600. The share price has ranged from 28.000 to 31.310 today, while the 52-week range spans from 5.260 to 31.310.
What Is the Biodesix Market Cap?
As of today, Biodesix market cap is 322.860M.
What Is the Biodesix (BDSX) Share Price Target?
The average 12-month share price target for Biodesix is 34.000, with a high estimate of 40 and a low estimate of 27. 7 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +11.11% Upside potential.
What Is Biodesix's Earnings Per Share (TTM)?
The Biodesix EPS (TTM) is -3.126.
When Is the Next Biodesix Earnings Date?
Biodesix will release its next earnings report on 30-10-2026.
From a Technical Analysis Perspective, Is BDSX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Biodesix Trade On?
Biodesix is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Biodesix?
The stock symbol for Biodesix is "BDSX."
How Many Times Has Biodesix Stock Split?
Biodesix has split 1 times.
How Many Employees Does Biodesix Have?
Biodesix has 334 employees.
What Is the BDSX After Hours Price?
BDSX's last after hours stock price is 30.155, the stock has changed by -0.445, or -1.450%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.